Biomarin is purchasing Prosensa for approximately $840 million.

Mdtech analyst that has allowed the WBB Securities cofounder to develop a reasoned perspective on how West Africa's Ebola epidemic might be humanely halted. Brozak also mentions small-cap names that could considerably enhance investors' portfolios.

U.S. stocks were mixed in a quiet session Thursday as rising hopes about more stimulus in Europe were tempered by a continuing decline in oil prices.

U.S. stocks surged Friday, with the Dow hitting an intraday record, joining a rally in Asian and European shares that was spurred by the Bank of Japan’s decision to unexpectedly expand its stimulus measures.

Novavax, Inc. will launch a Phase 1 clinical trial of an Ebola vaccine candidate in December.

On Monday morning, Sarepta Therapeutics (SRPT) held a teleconference concerning regulatory updates for Eteplirsen, the company's lead drug candidate for Duchenne Muscular Dystrophy.